Firazorexton
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C22H25F3N2O4S |
Molar mass | 470.51 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Firazorexton (INN) is an experimental orexin 2 (OX2) receptor agonist first described in a 2019 patent filed by Takeda Pharmaceutical Company.[1][2]
See also
- Orexin receptor § Agonists
- List of investigational sleep drugs § Orexin receptor agonists
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020.
Proposed INN: List 123
- ↑ WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.